Compare TNET & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | PGEN |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2000 | 2013 |
| Metric | TNET | PGEN |
|---|---|---|
| Price | $66.86 | $4.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $66.20 | $13.65 |
| AVG Volume (30 Days) | 352.7K | ★ 5.5M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.70 | 0.12 |
| Revenue | ★ $5,010,000,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $2,335.22 |
| Revenue Next Year | $4.82 | $85.34 |
| P/E Ratio | ★ $18.05 | $168.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $3.04 |
| 52 Week High | $76.59 | $8.98 |
| Indicator | TNET | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 32.63 |
| Support Level | $63.83 | $5.01 |
| Resistance Level | $71.56 | $5.47 |
| Average True Range (ATR) | 3.57 | 0.46 |
| MACD | -0.74 | -0.16 |
| Stochastic Oscillator | 41.48 | 13.23 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.